Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: Effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size

Journal of Cardiology

Volumn 63, Issue 1, 2014, Pages 60-68

  Tani, Shigemasa ^a,b   Matsumoto, Michiaki ^a,b   Nagao, Ken ^a,b   Hirayama, Atsushi ^b  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Low density lipoprotein heterogeneity; Triglyceride; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; SMOKING;

CORONARY ARTERY DISEASE; LOW-DENSITY LIPOPROTEIN HETEROGENEITY; TRIGLYCERIDE; TRIGLYCERIDE-RICH LIPOPROTEINS;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; RISK; TRIGLYCERIDES;

EID: 84891902428     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.06.018     Document Type: Article

References (27)

1. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., Boekholdt S.M., Khaw K.T., Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
2. Watts G.F., Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011, 97:350-356.
3. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., Goldberg A.C., Howard W.J., Jacobson M.S., Kris-Etherton P.M., Lennie T.A., Levi M., Mazzone T., Pennathur S., American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
4. Ip S., Lichtenstein A.H., Chung M., Lau J., Balk E.M. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009, 150:474-484.
5. Hirano T., Ito Y., Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscle Thromb 2005, 12:67-72.
6. Hoefner D.M., Hodel S.D., O'Brien J.F., Branum E.L., Sun D., Meissner I., McConnell J.P. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001, 47:266-274.
7. Mishima Y., Ando M., Kuyama F., Ishioka T., Kihata M. A simple method for identifying particle size of low-density lipoprotein using PAG electrophoresis: comparison between LipoPhor and Lipoprint LDL systems. Jpn Atheroscle Soc 1997, 25:67-70.
8. Nakano T., Inoue I., Seo M., Takahashi S., Awata T., Komoda T., Katayama S. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat Cardiovasc Drug Discov 2009, 4:31-36.
9. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T., Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Neurol 2007, 11:41-50.
10. Sniderman A.D., Blank D., Zakarian R., Bergeron J., Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003, 36:499-504.
11. Saiki A., Ohira M., Endo K., Koide N., Oyama T., Murano T., Miyashita Y., Shirai K. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract 2006, 74:242-248.
12. Hiro T., Kimura T., Morimoto T., Miyauchi K., Nakagawa Y., Yamagishi M., Ozaki Y., Kimura K., Saito S., Yamaguchi T., Daida H., Matsuzaki M., JAPAN-ACS Investigators Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronarysyndrome] study). J Am Coll Cardiol 2009, 54:293-302.
13. Miwa Y., Mitsuzumi H., Sunayama T., Yamada M., Okada K., Kubota M., Chaen H., Mishima Y., Kibata M. Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol (Tokyo) 2005, 51:460-470.
14. Tani S., Saito Y., Anazawa T., Kawamata H., Furuya S., Takahashi H., Iida K., Matsumoto M., Washio T., Kumabe N., Nagao K., Hirayama A. Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index differing in statin-treated patients with and without coronary artery disease: a case control study. Int Heart J 2011, 52:343-347.
15. Kondo A., Li J., Manabe M., Saito K., Kanno T., Maekawa M. Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J Atheroscle Thromb 2003, 10:72-78.
16. Sakurabayashi I., Saito Y., Kita T., Matsuzawa Y., Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta 2001, 312:87-95.
17. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
18. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31:149-164.
19. St-Pierre A.C., Cantin B., Dagenais G.R., Mauriège P., Bernard P.M., Després J.P., Lamarche B. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-559.
20. Thompson A., Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006, 259:481-492.
21. Iribarren C., Folsom A.R., Jacobs D.R., Gross M.D., Belcher J.D., Eckfeldt J.H. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study. The ARIC Study Investigators. Atherosclerosis Risk in Communities. Arterioscler Thromb Vasc Biol 1997, 17:1171-1177.
22. Rubenfire M., Brook R.D., Rosenson R.S. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010, 123:892-898.
23. Uemura Y., Watarai M., Ishii H., Koyasu M., Takemoto K., Yoshikawa D., Shibata R., Matsubara T., Murohara T. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
24. Nishiwaki M., Ikewaki K., Ayaori M., Mizuno K., Ohashi Y., Ohsuzu F., Ishikawa T., Nakamura H., MEGA Study Group Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study. J Cardiol 2013, 61:96-200.
25. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
26. Faergeman O., Holme I., Fayyad R., Bhatia S., Grundy S.M., Kastelein J.J., LaRosa J.C., Larsen M.L., Lindahl C., Olsson A.G., Tikkanen M.J., Waters D.D., Pedersen T.R., Steering Committees of IDEAL and TNT Trials Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009, 104:459-463.
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.